No data to show
OTCM
HSITF
Market cap1mUSD
Dec 30, Last price
0.12USD
Name
HBL Hadasit Bio Holdings Ltd
Chart & Performance
P/E
—
P/S
—
EPS
—
Div Yield, %
—
Shrs. gr., 5y
—
Rev. gr., 5y
-61.84%
Revenues
0k
Net income
-29m
L-6.48%
CFO
-2m
L-6.48%
Dividend
Feb 06, 20190.588094 USD/sh
Profile
Hadasit Bio-Holdings Ltd operates in the biotechnology industry in Israel. It primarily focuses on the therapeutic areas, including oncology, regenerative medicine, and inflammatory disease. The company offers ProtAb, an immunotherapeutic monoclonal antibody for the treatment of autoimmune inflammatory diseases. Hadasit Bio-Holdings Ltd was founded in 2005 and is based in Jerusalem, Israel.
Valuation
Title ILS in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|
| 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2016‑12 | 2015‑12 | |
| Income | |||||||||
Revenues | |||||||||
Cost of revenue | 1,781 | 1,853 | |||||||
Unusual Expense (Income) | |||||||||
NOPBT | (1,781) | (1,853) | |||||||
NOPBT Margin | |||||||||
Operating Taxes | |||||||||
Tax Rate | |||||||||
NOPAT | (1,781) | (1,853) | |||||||
Net income | (29,187) -6.48% | (31,211) -210.04% | |||||||
Dividends | |||||||||
Dividend yield | |||||||||
Proceeds from repurchase of equity | |||||||||
BB yield | |||||||||
| Debt | |||||||||
Debt current | 1,576 | 1,523 | |||||||
Long-term debt | 1,409 | ||||||||
Deferred revenue | |||||||||
Other long-term liabilities | |||||||||
Net debt | (6,460) | (20,791) | |||||||
| Cash flow | |||||||||
Cash from operating activities | (1,978) | (2,115) | |||||||
CAPEX | |||||||||
Cash from investing activities | 3,251 | (3,173) | |||||||
Cash from financing activities | (1,671) | 3,163 | |||||||
FCF | (1,778) | (1,850) | |||||||
| Balance | |||||||||
Cash | 8,036 | 15,863 | |||||||
Long term investments | 7,860 | ||||||||
Excess cash | 8,036 | 23,723 | |||||||
Stockholders' equity | (129,346) | (100,159) | |||||||
Invested Capital | 136,859 | 138,169 | |||||||
ROIC | |||||||||
ROCE | |||||||||
| EV | |||||||||
Common stock shares outstanding | 11,088 | 11,088 | |||||||
Price | |||||||||
Market cap | |||||||||
EV | |||||||||
EBITDA | (1,778) | (1,850) | |||||||
EV/EBITDA | |||||||||
Interest | 191 | 118 | |||||||
Interest/NOPBT | |||||||||